Page last updated: 2024-11-02

pantoprazole and Helicobacter Infections

pantoprazole has been researched along with Helicobacter Infections in 199 studies

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.

Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.

Research Excerpts

ExcerptRelevanceReference
"In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions."9.14Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010)
"To compare the efficacy and tolerability of pantoprazole 20 mg once daily with that of esomeprazole 20 mg once daily for 6 months as maintenance therapy in patients with previously healed gastroesophageal reflux disease."9.12Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. ( Benamouzig, R; Goh, KL; Sander, P; Schwan, T, 2007)
"To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease."9.10Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003)
"To study the efficacy of three pantoprazole-based triple therapy regimens for the eradication of Helicobacter pylori infection and gastric ulcer healing."9.10Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003)
" pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study."9.09Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001)
" pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b."9.09Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999)
" pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40."9.09Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999)
" The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H."9.08Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997)
"Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis."8.82Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004)
"3%) and there were no serious adverse events."6.71The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004)
"Clarithromycin resistance was detected in 33/190 patients (17."5.51Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. ( Chang, YW; Cho, JH; Jang, JY; Kim, JW; Ko, WJ; Moon, JR; Oh, CH; Oh, SJ; Park, YM, 2019)
"Treatment with clarithromycin, metronidazole and pantoprazole eradicated H."5.31Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001)
"The use of esomeprazole rather than pantoprazole increases the probability of achieving resolution of heartburn during reflux oesophagitis-healing therapy."5.14Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. ( Armstrong, D; Eklund, S; Labenz, J; Leodolter, A; Zetterstrand, S, 2009)
"In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions."5.14Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010)
"To compare the efficacy and tolerability of pantoprazole 20 mg once daily with that of esomeprazole 20 mg once daily for 6 months as maintenance therapy in patients with previously healed gastroesophageal reflux disease."5.12Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. ( Benamouzig, R; Goh, KL; Sander, P; Schwan, T, 2007)
" pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b."5.11Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. ( Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z, 2004)
" pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks)."5.10[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection]. ( Cui, M; Hu, F; Jiang, H; Zheng, X, 2002)
"To study the efficacy of three pantoprazole-based triple therapy regimens for the eradication of Helicobacter pylori infection and gastric ulcer healing."5.10Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003)
"To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease."5.10Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003)
"To compare the efficacy of lansoprazole and pantoprazole in treatment of active duodenal ulcer and Helicobacterpylori eradication."5.10In treatment of active duodenal ulcer and Helicobacter pylori eradication. ( Karaoglu, AO; Yasa, MH; Yukselen, V, 2003)
"Non-ulcer dyspepsia patients (n=199), with a normal upper endoscopy and a positive (13)C-urea breath test (UBT) were randomly assigned to either pantoprazole, clarithromycin and metronidazole (PCM) or pantoprazole, clarithromycin and eicosapen (PCE) for 7 days."5.09Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. ( Drewe, J; Geiser, HR; Meier, R; Wettstein, A, 2001)
"For this open study, 331 patients with duodenal ulcer were screened and randomly allocated to either pantoprazole 40 mg b."5.09Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. ( Daake, H; Frevel, M; Janisch, HD; Kellner, HU; Krezdorn, HG; Tanneberger, D; Wack, R, 2000)
" pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40."5.09Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999)
" pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b."5.09Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999)
"In this open, randomized, monocenter, parallel group comparison, 107 patients with duodenal ulcer or functional dyspepsia were assigned to receive one of the following treatment regimens: a 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid, which was either preceded or followed by a 7-day therapy with pantoprazole, 40 mg (P-PCM or PCM-P)."5.09Pantoprazole suppresses Helicobacter pylori without affecting cure. ( Adamek, RJ; Pfaffenbach, B; Szymanski, C, 1999)
" pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study."5.09Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001)
"pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd."5.08[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995)
" The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H."5.08Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997)
"Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis."4.82Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004)
"Pantoprazole is a proton pump inhibitor that is commonly used in the treatment of peptic ulcer disease (PUD) and metabolized by cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4."3.85Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ( Altinbas, A; Babaoglu, MO; Bozkurt, A; Goktas, MT; Kalkisim, S; Karaca, RO; Kilincalp, S; Yasar, U; Yuksel, I, 2017)
"Following healing of endoscopically confirmed peptic ulcer or reflux oesophagitis during 4-12 weeks' treatment with pantoprazole (40-80 mg/day), adult patients received open-label maintenance treatment with pantoprazole (40-160 mg/day) for up to 15 years in a single centre combined study (10-year initial study; 5-year extension study)."3.78Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. ( Athmann, C; Brunner, G; Schneider, A, 2012)
" pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole."3.76Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. ( Bielicki, D; Droździk, M; Gawrońska-Szklarz, B; Kurzawski, M; Marlicz, W; Siuda, A, 2010)
"The development of eosinophilic gastritis immediately after Helicobacter pylori eradication has not previously been described: A 62-year-old woman developed eosinophilic gastritis immediately after a triple therapy for Helicobacter pylori eradication, consisting of pantoprazole, amoxicillin and clarithromycin."3.74[Eosinophilic gastritis after helicobacter pylori eradication]. ( Aigner, T; Fritzsch, J; Krügel, V; Pluta, L; Schütz, A, 2008)
"This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years."3.73Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. ( Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005)
"The rise in serum gastrin and pepsinogen I after 5 days' treatment with the proton pump inhibitor pantoprazole (40 mg/day) was examined in eight duodenal ulcer patients with Helicobacter pylori infection and compared with eight in whom it had been eradicated."3.68Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy. ( Dorrian, CA; Fullarton, GM; Harwood, J; Macdonald, AM; McColl, KE; Nujumi, AM, 1992)
"Clarithromycin resistance was an independent risk factor predicting eradication failure in standard triple group (P < 0."2.80A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. ( Chen, A; Chen, WC; Cheng, JS; Chuah, SK; Hsu, PI; Kao, SS; Lai, KH; Peng, NJ; Tsay, FW; Wang, HM; Wu, DC; Yu, HC, 2015)
"Halitosis was significantly more prevalent in the group of patients with persistent H."2.80Eradication of gastric Helicobacter pylori ameliorates halitosis and tongue coating. ( Bojic, B; Milasin, J; Popovic, B; Zaric, S, 2015)
"SUMMARY Eradikacion therapy at patients with chronic pancreatitis and combined with Helicobacter associated erosive gastropathy in a month after treatment appeared successful at 75% patients which accepted therapy of the first line--pantoprazol, amoksicillin, klaritromicin."2.79[Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy]. ( Kotsiubniak, LA; Koval', VIu; Moskal', OM, 2014)
" Possibly, it can be improved by alterations in dose, dosing intervals, and/or duration."2.77A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. ( Bari, Z; Fakheri, H; Sardarian, H, 2012)
"The optimal dosage of intravenous proton pump inhibitors (PPIs) for the prevention of peptic ulcer rebleeding remains unclear."2.77Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. ( Chen, CC; Fang, YJ; Han, ML; Hsu, SJ; Hu, FC; Lee, JY; Lin, JT; Lin, TL; Liou, JM; Tseng, PH; Wang, HP; Wu, MS, 2012)
"Erdosteine is an efficient adjuvant therapy that could be used in conjunction with first-line triple therapy in the treatment of H."2.75Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study. ( Abut, E; Bölükbaş, C; Bölükbaş, FF; Dalay, AR; Güveli, H; Kurdaş, OO; Yaşar, B, 2010)
"Fifty-six consecutive patients with type 2 diabetes mellitus and 58 age- and sex-matched control patients were included in the study."2.74Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. ( Arslan, H; Demir, M; Gokturk, HS; Ozturk, NA; Serin, E; Yilmaz, U, 2009)
"Pantoprazole (40 mg/day) was given to 27 patients for 28 days and ranitidine (300 mg."2.74Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment. ( Dağalp, K; Ilgan, S; Ozgüven, M; Oztürk, E; Yeşilova, Z, 2009)
"Treatment with omeprazole or pantoprazole prior to urea breath test (UBT) was associated with low false negative results, while lansoprazole and esomeprazole caused clinically unacceptable high false negative rates (pantoprazole 2."2.71Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. ( Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H, 2004)
" Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0."2.71Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. ( Biagini, R; Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansi, C; Mele, MR; Savarino, V; Tessieri, L; Usai, P; Vigneri, S; Zentilin, P, 2003)
"3%) and there were no serious adverse events."2.71The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004)
" Treatment was safe; only four patients had adverse events definitely related to pantoprazole."2.70Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001)
" No studies have yet compared the effects of different dosages of clarithromycin in combination with a proton pump inhibitor and amoxicillin in elderly patients."2.70Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ( Bozzola, L; Di Mario, F; Franceschi, M; Leandro, G; Pilotto, A; Rassu, M; Soffiati, G; Valerio, G, 2001)
"Metronidazole resistance was found in 44% of pre-treatment cultures of H."2.69Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. ( Axon, AT; Bardhan, KD; Braun, W; Cooper, BT; Dillon, J; Gatz, G; Tildesley, G; Wyatt, JI, 2000)
" pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently."2.69Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. ( Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000)
"Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion."2.42Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003)
"We undertook a broad data review of the efficacy of nine different 7-day triple therapies consisting of a proton pump inhibitor (lansoprazole, pantoprazole, omeprazole) in its standard dosage and two antibiotics."2.42Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. ( Beckerling, A; Gatz, G; Ulmer, HJ, 2003)
" Pantoprazole is well absorbed when administered as an enteric-coated, delayed-release tablet, with an oral bioavailability of approximately 77%."2.41Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000)
" Adverse drug effects were found in 36 patients from the twice a day group and 50 patients from the four times a day group (P = ."1.56Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. ( Kim, JH; Kim, JY; Lee, SY; Park, HS; Sung, IK, 2020)
"Clarithromycin resistance was detected in 33/190 patients (17."1.51Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. ( Chang, YW; Cho, JH; Jang, JY; Kim, JW; Ko, WJ; Moon, JR; Oh, CH; Oh, SJ; Park, YM, 2019)
"Curcumin was filtered using Lipinski's rule of five and the druglikeness property for evaluation of pharmacological properties."1.42In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation. ( Roy, BK; Shukla, HS; Srivastava, AK; Tewari, M, 2015)
"The mucosal folds in Menetrier's disease are often most prominent in the body and fundus."1.37[A case of Menetrier's disease showing mucus bridge observed during endoscopy]. ( Hwang, JM; Kim, GH; Kim, WJ; Lee, HS; Lee, HW; Park, DY; Ryu, DY; Song, GA, 2011)
"Burkitt's lymphoma is a highly aggressive non-Hodgkin lymphoma, often presenting in extra-nodal sites."1.35Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. ( Baia, M; Baumgaertner, I; Charachon, A; Copie-Bergman, C; Delchier, JC; Haioun, C; Levy, M; Sobhani, I, 2009)
"Proton pump inhibitors play an important role in increasing the bioavailability of antibiotics in the gastric mucus by altering gastric volumes and increasing the stability of some antibiotics, e."1.33Helicobacter pylori: factors affecting eradication and recurrence. ( Vakil, N, 2005)
"Metronidazole is a good substitute for clarithromycin as the second-line option for children."1.32Results of triple eradication therapy in Japanese children: a retrospective multicenter study. ( Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N, 2004)
"Metronidazole resistance was reported in a high percentage of strains isolated from patients."1.31Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients. ( Cheah, P; Chin, S; Goh, K; Parasakthi, N; Ranjeev, C; Rosmawati, M; Tan, Y, 2000)
"Treatment with clarithromycin, metronidazole and pantoprazole eradicated H."1.31Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001)

Research

Studies (199)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's29 (14.57)18.2507
2000's103 (51.76)29.6817
2010's64 (32.16)24.3611
2020's3 (1.51)2.80

Authors

AuthorsStudies
Jain, KS1
Shah, AK1
Bariwal, J1
Shelke, SM1
Kale, AP1
Jagtap, JR1
Bhosale, AV1
Jha, SK1
Mishra, MK1
Saharawat, K1
Jha, P1
Purkayastha, S1
Ranjan, R1
Kim, JY2
Lee, SY1
Kim, JH2
Sung, IK1
Park, HS1
Şenocak Taşçı, E1
Akbaş, T1
Jonaitis, P1
Jonaitis, L1
Kupcinskas, J1
Souto Filho, JTD1
Lemos, LVB1
Vieira Junior, MC1
Barboza, KP1
Castelar, BM1
Ribeiro, AEL1
da Silva, FC1
Boal Carvalho, P1
Magalhães, J1
Dias de Castro, F1
Rosa, B1
Cotter, J1
Tsay, FW6
Wu, DC5
Yu, HC5
Kao, SS4
Lin, KH1
Cheng, JS3
Wang, HM5
Chen, WC5
Sun, WC1
Tsai, KW2
Hsu, PI7
Park, JS2
Park, JE1
Oh, BS1
Yoon, BW1
Kim, HK1
Lee, JW1
Kim, NH1
Cho, WS1
Woo, YS1
Jahng, J1
Kim, YS2
Pan, CY1
Kao, JY1
Peng, NJ4
Tsai, TJ1
Chen, CL1
Chang, YW1
Ko, WJ1
Oh, CH1
Park, YM1
Oh, SJ2
Moon, JR1
Cho, JH1
Kim, JW2
Jang, JY1
Ennkaa, A1
Shaath, N1
Salam, A1
Mohammad, RM1
Joosten, M1
Flahou, B1
Meyns, T1
Smet, A1
Arts, J1
De Cooman, L1
Pasmans, F1
Ducatelle, R1
Haesebrouck, F1
Cecchini, MP1
Pellegrini, C1
Bassetto, MA1
Osculati, F1
Sbarbati, A1
Marcolini, L1
Pegoraro, M1
Fontana, R1
De Franceschi, L1
Nasa, M1
Choksey, A1
Phadke, A1
Sawant, P1
Trifan, A1
Girleanu, I1
Cojocariu, C1
Sfarti, C1
Singeap, AM1
Dorobat, C1
Grigore, L1
Stanciu, C1
Tseng, HH4
Lai, KH5
Chen, A3
Berry, AC1
Nakshabendi, R1
Baltz, AC1
Metanat, HA1
Valizadeh, SM1
Fakheri, H4
Maleki, I2
Taghvaei, T3
Hosseini, V3
Bari, Z3
Koval', VIu1
Kotsiubniak, LA1
Moskal', OM1
Almeida, N1
Donato, MM1
Romãozinho, JM1
Luxo, C1
Cardoso, O1
Cipriano, MA1
Marinho, C1
Fernandes, A1
Calhau, C1
Sofia, C1
Hauser, G1
Salkic, N1
Vukelic, K1
JajacKnez, A1
Stimac, D3
Srivastava, AK1
Tewari, M1
Shukla, HS1
Roy, BK1
Zaric, S2
Bojic, B2
Popovic, B2
Milasin, J2
Sapmaz, F1
Kalkan, IH1
Suslu, I1
Demirci, H1
Atasoy, P1
Guliter, S1
Gungor, G1
Baglıcakoglu, M1
Kayacetin, E1
Biyik, M1
Ucar, R1
Goktepe, H1
Ataseven, H3
Demir, A1
Curth, HM1
Dinter, J1
Nigemeier, K1
Kütting, F1
Hunzelmann, N1
Steffen, HM1
Apostolopoulos, P1
Koumoutsos, I1
Ekmektzoglou, K1
Dogantzis, P1
Vlachou, E1
Kalantzis, C1
Tsibouris, P1
Alexandrakis, G1
Chuah, SK1
Chan, CC1
Chien, NH1
Lee, CL1
Yang, YC1
Hung, CS1
Tu, TC1
Wu, CH1
Ciccaglione, AF2
Tavani, R1
Grossi, L2
Cellini, L2
Manzoli, L1
Marzio, L2
Ormeci, A1
Emrence, Z1
Baran, B1
Gokturk, S2
Soyer, OM1
Evirgen, S1
Akyuz, F1
Karaca, C1
Besisik, F1
Kaymakoglu, S1
Ustek, D1
Demir, K1
Dore, MP2
Soro, S1
Rocchi, C1
Loria, MF1
Bibbò, S1
Pes, GM1
Park, SM1
Kim, JS3
Kim, BW1
Ji, JS1
Choi, H1
Karaca, RO1
Kalkisim, S1
Altinbas, A1
Kilincalp, S1
Yuksel, I1
Goktas, MT1
Yasar, U1
Bozkurt, A1
Babaoglu, MO1
Marušić, M2
Dominković, L1
Majstorović Barać, K1
Gulić, S1
Bago, J1
Pezerović, D2
Çekin, AH1
Şahintürk, Y1
Akbay Harmandar, F1
Uyar, S1
Yolcular, BO1
Çekin, Y1
Jung, HS1
Shim, KN1
Baik, SJ1
Na, YJ1
Kang, MJ1
Jung, JM1
Ha, CY1
Jung, SA1
Yoo, K1
Kang, JM1
Kim, N3
Lee, DH3
Park, YS2
Chang, IJ1
Song, IS3
Jung, HC3
Villoria, A1
Garcia, P1
Calvet, X3
Gisbert, JP5
Vergara, M2
Oh, JH1
Dong, MS1
Choi, MG1
Yoo, HW1
Lee, SB1
Park, YI1
Chung, IS1
Fritzsch, J1
Krügel, V1
Aigner, T1
Pluta, L1
Schütz, A1
Hong, EJ1
Park, DI2
Song, MJ1
Choi, WH1
Hong, CH1
Park, JH1
Kim, HJ2
Cho, YK2
Shon, CI1
Jeon, WK2
Kim, BI2
Labenz, J3
Armstrong, D1
Zetterstrand, S1
Eklund, S1
Leodolter, A2
Pellicano, R1
Oztürk, E1
Yeşilova, Z3
Ilgan, S2
Ozgüven, M1
Dağalp, K2
Jankovic, Lj1
Dapcevic, B1
Cakic, S1
Hunfeld, NG1
Touw, DJ1
Mathot, RA1
Mulder, PG1
VAN Schaik, RH1
Kuipers, EJ1
Kooiman, JC1
Geus, WP1
Ng, FH1
Wong, SY1
Lam, KF1
Chu, WM1
Chan, P1
Ling, YH1
Kng, C1
Yuen, WC1
Lau, YK1
Kwan, A1
Wong, BC1
Demir, M5
Gokturk, HS2
Ozturk, NA3
Arslan, H1
Serin, E3
Yilmaz, U3
Dabos, KJ1
Sfika, E1
Vlatta, LJ1
Giannikopoulos, G1
Baumgaertner, I1
Copie-Bergman, C1
Levy, M1
Haioun, C1
Charachon, A1
Baia, M1
Sobhani, I1
Delchier, JC1
Gen, R2
Abut, E1
Yaşar, B1
Güveli, H1
Bölükbaş, C1
Bölükbaş, FF1
Dalay, AR1
Kurdaş, OO2
Gawrońska-Szklarz, B2
Siuda, A1
Kurzawski, M1
Bielicki, D1
Marlicz, W1
Droździk, M2
Cetinkaya, ZA1
Sezikli, M1
Güzelbulut, F1
Coşgun, S1
Düzgün, S1
Lassnig, RM1
Chang, AH1
Haggerty, TD1
de Martel, C1
Leung, CW1
Parsonnet, J1
Qua, CS1
Manikam, J1
Goh, KL2
Yakut, M1
Çinar, K1
Seven, G1
Bahar, K1
Özden, A1
Hwang, JM1
Kim, GH2
Kim, WJ1
Lee, HS1
Lee, HW1
Ryu, DY2
Song, GA2
Park, DY1
Cheong, JH1
Lee, BE1
Choi, MK1
Moon, JY1
Kim, DU1
Gu, LY1
Lin, WW1
Lu, H1
Chen, XY1
Ge, ZZ1
Li, XB1
Chung, JW1
Lee, JH2
Jung, HY1
Yun, SC1
Oh, TH1
Choi, KD1
Song, HJ1
Lee, GH1
Farina, V1
Cuccu, M1
Mameli, L1
Massarelli, G1
Graham, DY2
Wang, KM1
Lee, CC1
Chang, SN1
Park, HK1
Jo, HJ1
Shin, CM1
Lee, SH1
Hwang, JH1
Jeong, SH1
Nam, RH1
Kim, JM2
Kim, SJ1
Yoon, JH1
Suk, KT1
Kim, JB1
Kim, DJ1
Kim, DY1
Min, HJ1
Park, SH1
Shin, WG1
Kim, KH1
Kim, HY1
Baik, GH1
Holtmann, G2
van Rensburg, C1
Schwan, T2
Sander, P2
Siffert, W1
Kım, KJ1
Park, MI1
Park, SJ1
Cho, SW1
Moon, W1
Kim, GM1
Kim, WM1
Shcherbakov, PL1
Ianova, OB1
Belousova, NL1
Masharova, AA1
Shcherbakova, MIu1
Goncharenko, LS1
Firsova, LD1
Kim, VA1
Govorun, VM1
Kashnikov, VS1
Chen, CC1
Lee, JY1
Fang, YJ1
Hsu, SJ1
Han, ML1
Tseng, PH1
Liou, JM1
Hu, FC1
Lin, TL1
Wu, MS1
Wang, HP1
Lin, JT1
Brunner, G1
Athmann, C1
Schneider, A2
Sardarian, H2
Gashi, Z1
Joksimovic, N1
Dragusha, G1
Bakalli, A1
Mokhtare, M1
Boixeda, D3
Bermejo, F2
Martín-De-Argila, C1
López-Sanromán, A1
Defarges, V1
Hernández-Ranz, F1
Milicua, JM1
García-Plaza, A1
Queiroz, DM1
Dani, R1
Silva, LD1
Santos, A1
Moreira, LS1
Rocha, GA1
Corrêa, PR1
Reis, LF1
Nogueira, AM1
Alvares Cabral, MM1
Esteves, AM1
Tanure, J1
Cui, M1
Hu, F1
Jiang, H1
Zheng, X1
Cheer, SM1
Prakash, A1
Faulds, D1
Lamb, HM1
Dulbecco, P1
Gambaro, C1
Bilardi, C1
Zentilin, P1
Mele, MR1
Mansi, C1
Biagini, R1
Tessieri, L1
Iiritano, E1
Usai, P1
Vigneri, S1
Savarino, V2
Ulmer, HJ1
Beckerling, A1
Gatz, G3
Malfertheiner, P2
Kirchner, T2
Kist, M2
Peitz, U2
Strobel, S2
Bohuschke, M1
Martín De Argila, C2
López Sanromán, A1
Hernández Ranz, F1
García Plaza, A2
de Boer, SY1
v d Meeberg, PC1
Siem, H1
de Boer, WA1
Perri, F6
Festa, V4
Merla, A1
Barberani, F1
Pilotto, A6
Andriulli, A5
Bochenek, WJ2
Peters, S1
Fraga, PD2
Wang, W1
Mack, ME2
Osato, MS1
El-Zimaity, HM1
Davis, KD1
Khorrami, S1
Pajares, JM2
Singh, G1
Levine, A1
Shevah, O1
Shabat-Sehayek, V1
Aeed, H1
Boaz, M1
Moss, SF1
Niv, Y1
Avni, Y1
Shirin, H1
Wu, CJ2
Lo, GH2
Lo, CC2
Lin, CK2
Shie, CB1
Jou, HS1
Tsai, PM1
Chen, JL2
Yukselen, V1
Yasa, MH1
Karaoglu, AO1
Ghazzawi, IM1
Obeidat, WA1
Zuriekat, FA1
Sivri, B1
Simsek, I1
Hulagu, S1
Kadayifci, A4
Tozun, N1
Akarsu, M1
Uraz, S1
Savas, MC2
Koruk, M1
Bozbas, A1
Franceschi, M4
Longoa, MG1
Scarcelli, C1
Orsitto, G1
Perri, FC1
D'Ambrosio, LP1
Leandro, G5
Kato, S1
Konno, M1
Maisawa, S1
Tajiri, H1
Yoshimura, N1
Shimizu, T1
Toyoda, S1
Nakayama, Y1
Iinuma, K1
Buzás, GM2
Metz, DC1
Bardhan, KD5
Bishop, AE2
Polak, JM2
Romanska, HM1
Rowland, A2
Thompson, M3
Morris, P3
Schaefer-Preuss, S1
Luehmann, R1
McCaldin, B3
Calleja, JL1
Suarez, M1
De Tejada, AH1
Navarro, A1
Babic, Z1
Nesanovic, M1
Lucijanic-Mlinac, M1
Stajcar, V1
Wrześniewska, J1
Starzyńska, T1
Pawlik, A1
Safranow, K1
Ferenc, K1
Uygun, A2
Ateş, Y1
Karslioğlu, Y1
Ciğerim, M1
Bağci, S1
Yamaoka, Y1
Vakil, N1
Okazaki, K1
Mori, S1
Tahashi, K1
Borody, TJ1
Pang, G1
Wettstein, AR1
Clancy, R1
Herdman, K1
Surace, R1
Llorente, R1
Ng, C1
Aladağ, M1
Kantarçeken, B1
Karincaoğlu, M1
Sertkaya, A1
Cikim, K1
Harputluoğlu, MM1
Demirel, U1
Alan, H1
Ateş, F1
Yildirim, B1
Hilmioğlu, F1
Manes, G1
Ferrara, EC1
Porro, GB1
Sezgin, O3
Altintaş, E3
Uçbilek, E3
Tataroğlu, C1
Cheon, JH1
Kim, SG1
Dietrich, JW1
Boehm, BO1
Ziemniak, W1
Yilmaz, S1
Bayan, K1
Dursun, M1
Canoruç, F1
Kilinç, N1
Tüzün, Y1
Daniş, R1
Ertem, M1
González Carro, P1
Pérez Roldán, F1
De Pedro Esteban, A1
Legaz Huidobro, ML1
Soto Fernández, S1
Roncero Garcia Escribano, O1
Esteban López-Jamar, JM1
Pedraza Martin, C1
Ruíz Carrillo, F1
Hartmann, D1
Eickhoff, A1
Damian, U1
Riemann, JF1
Schilling, D1
Benamouzig, R1
Di Mario, F3
Cavallaro, LG1
Nouvenne, A1
Stefani, N1
Cavestro, GM1
Iori, V1
Maino, M1
Comparato, G1
Fanigliulo, L1
Morana, E1
Martelli, L1
Martelli, M1
Franzè, A1
Mahachai, V1
Thong-Ngam, D1
Noophun, P1
Tumwasorn, S1
Kullavanijaya, P1
Tombak, A1
Tellioğlu, B1
Nayir, E1
Choi, HS1
Hwang, SJ1
Sohn, CI1
Széles, I1
Safali, M1
Karaeren, N1
Abdullahi, M1
Annibale, B1
Capoccia, D1
Tari, R1
Lahner, E1
Osborn, J1
Leonetti, F1
Severi, C1
Tillenburg, B2
Becker, T1
Börsch, G1
Stolte, M4
Adamek, RJ6
Szymanski, C4
Pfaffenbach, B4
Opferkuch, W1
Ricken, D1
Wegener, M1
Weismüller, J1
Lütke, A1
Seelis, RE1
Dohmen, W1
Glaser, J1
Hein, J1
Daikeler, R1
Weithofer, G1
Vieth, M1
Schmidt, M1
Treiber, G1
Lambert, JR1
Louw, JA1
van Rensburg, CJ1
Hanslo, D1
Grundlings, HD1
Girdwood, AH1
Marks, IN1
Morton, D1
Slater, DN1
Perry, MJ2
Cherian, P2
Jones, RB1
Brookes, A1
Ellenrieder, V2
Fensterer, H1
Waurick, M1
Adler, G2
Glasbrenner, B2
Améndola, R1
Roldán, CD1
Morgade, L1
Solagna, A1
Lineado, A1
Musi, AO1
Valero, J1
Zerbo, O1
Kogan, Z1
Ferro, FE1
Schenone, L1
Corti, R1
Pazzi, P1
Scagliarini, R1
Gamberini, S1
Matarese, V1
Rizzo, C1
Gullini, S1
Bethke, TD1
Meier, E1
Meining, A1
Dattilo, M1
Figura, N1
Cammarota, G2
Papa, A1
Cianci, R1
Cannizzaro, O1
Armuzzi, A3
Gasbarrini, A3
Addolorato, G1
Gasbarrini, GB1
Abdul Aal, GM1
Dajani, AI2
Nounou, M1
Awad, S2
Abdul Rasheed, Z2
Gautam, S2
Ukabam, S2
Nayal, S2
Nounou, MA1
Abdul Aal, G1
Cain, C1
Catalano, F2
Branciforte, G2
Catanzaro, R2
Bentivegna, C2
Cipolla, R2
Nuciforo, G2
Brogna, A2
Rodríguez Téllez, M1
Valenzuela Barranco, M1
Caballero Plasencia, A1
Martín Ruiz, J1
López-Andrade, A1
Carmona Soria, I1
Herrerías Gutiérrez, J1
Boeck, W1
Richter, C1
Marre, R1
Lamouliatte, H2
Samoyeau, R2
De Mascarel, A2
Megraud, F2
Dillon, J1
Axon, AT1
Cooper, BT1
Tildesley, G1
Wyatt, JI1
Braun, W1
Vcev, A2
Ivandić, A2
Vceva, A2
Takac, B2
Dammann, HG1
Fölsch, UR1
Hahn, EG1
von Kleist, DH1
Klör, HU1
Schweeger, I1
Fitscha, P1
Sinzinger, H1
Ojetti, V2
Pitocco, D1
Silveri, NG1
Pola, P2
Ghirlanda, G1
Gasbarrini, G2
Carpio, D1
Marcos, S1
Gisbert, JL1
García Grávalos, R1
Vukobrat-Bijedić, Z1
Lacević, N1
Bratović, I1
Gribajcević, M1
Gogov, B1
Radović, S1
Battaglia, G1
Germanà, B1
Marin, R1
Valerio, G2
Frevel, M1
Daake, H1
Janisch, HD1
Kellner, HU1
Krezdorn, HG1
Tanneberger, D1
Wack, R1
Howden, CW1
Goh, K1
Parasakthi, N1
Cheah, P1
Ranjeev, C1
Rosmawati, M1
Tan, Y1
Chin, S1
Giannini, E1
Romagnoli, P1
Fasoli, A1
Chiarbonello, B1
Malfatti, F1
Botta, F1
Risso, D1
Lantieri, PB1
Testa, R1
Jungnickel, PW1
Calabrese, C1
Di Febo, G1
Areni, A1
Scialpi, C1
Biasco, G1
Miglioli, M1
Tincani, E1
Bertoni, G1
Silingardi, M1
Ghirarduzzi, A1
Bedogni, G1
Iori, I1
Rosandić, M1
Cremonini, F1
Bartolozzi, F1
Canducci, F1
Candelli, M1
Santarelli, L1
De Lorenzo, A1
Clemente, R1
Villani, MR3
Quitadamo, M3
Caruso, N1
Bergoli, ML1
Broutet, N1
Marais, A1
Salamon, R1
Meier, R1
Wettstein, A1
Drewe, J1
Geiser, HR1
Bardou, M1
Romanska, H1
Fischer, R2
Ng, W1
Lühmann, R1
Annese, V1
Niro, GA1
Bozzola, L1
Rassu, M1
Soffiati, G1
Behrendt, J1
Wenzel, C1
Herszényi, L1
Tulassay, Z1
Mayr-Kanhäuser, S1
Kränke, B1
Kaddu, S1
Müllegger, RR1
Kurbel, S1
Ostojić, R1
Barbir, A1
Hovat, D1
Mihaljević, S1
Barth, J1
Hahne, W1
Parente, F1
Sainaghi, M1
Sangaletti, O1
Imbesi, V1
Maconi, G1
Anderloni, A1
Bianchi Porro, G1
Vallve, M1
Gościmski, A1
Matras, J1
Wallner, G1
Meneghelli, UG1
Boaventura, S1
Moraes-Filho, JP1
Leitão, O1
Ferrari, AP1
Almeida, JR1
Magalhães, AF1
Castro, LP1
Haddad, MT1
Tolentino, M1
Jorge, JL1
Silva, E1
Maguilnik, I1
McColl, KE1
Nujumi, AM1
Dorrian, CA1
Macdonald, AM1
Fullarton, GM1
Harwood, J1

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes[NCT05449028]230 participants (Anticipated)Interventional2022-05-01Recruiting
Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864]330 participants (Actual)Interventional2013-07-31Completed
Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038]352 participants (Actual)Interventional2015-02-28Completed
Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan[NCT01769365]Phase 4307 participants (Actual)Interventional2010-07-31Completed
A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255]Phase 4364 participants (Actual)Interventional2017-01-30Completed
"Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"[NCT01464060]Phase 4400 participants (Anticipated)Interventional2011-09-30Recruiting
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]228 participants (Actual)Interventional2012-01-31Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.[NCT00841854]Phase 4199 participants (Actual)Interventional2008-06-30Completed
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT05049902]Phase 41,300 participants (Actual)Interventional2021-09-21Completed
The Efficacy of Bismuth-containing Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection in 10 Days and 14 Days: a Prospective, Randomized, Controlled Study[NCT05586113]Phase 4398 participants (Anticipated)Interventional2023-02-06Not yet recruiting
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT04901117]Phase 41,300 participants (Anticipated)Interventional2021-06-30Not yet recruiting
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435]440 participants (Actual)Interventional2012-10-31Completed
High Dose Versus Standard Dose Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Hemostasis: A Prospective Randomized Comparative Study[NCT00709046]150 participants (Anticipated)Interventional2008-01-31Recruiting
Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes[NCT02345239]Phase 314 participants (Anticipated)Interventional2015-02-28Not yet recruiting
Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection[NCT04652284]Phase 3300 participants (Anticipated)Interventional2021-05-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants in Which H. Pylori Was Eradicated

Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy

Interventionparticipants (Number)
Pantoprazole+Bismuth+Tetra+Metro154
Hybrid Therapy154

Number of Participants in Which H. Pylori Was Eradicated

Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy

Interventionparticipants (Number)
Pantoprazole+Bismuth+Tetra+Metro169
(Panto+Amox+Clar+Metr)+(Panto+Amox)170

Number of Participants With Complete Eradication of Helicobacter Pylori

Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT01769365)
Timeframe: at the 6th week after the end of anti- H. pylori therapy

Interventionparticipants (Number)
7-day Quadruple Therapy102
10-day Sequential Therapy100
7-day Standard Triple Therapy101

Number of Participants With Healed Peptic Ulcer

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Interventionparticipants (Number)
Histamine-2 Receptor Antagonist Group106
Placebo Group101

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

Number of Participants in Which H. Pylori Was Eradicated

Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy

Interventionparticipants (Number)
Reverse Hybrid Therapy206
Standard Triple Therapy191

Reviews

21 reviews available for pantoprazole and Helicobacter Infections

ArticleYear
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
    Bioorganic & medicinal chemistry, 2007, Feb-01, Volume: 15, Issue:3

    Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans;

2007
Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based
    Current drug metabolism, 2020, Volume: 21, Issue:11

    Topics: Cytochrome P-450 CYP2C19; Helicobacter Infections; Humans; Pantoprazole; Polymorphism, Genetic; Prot

2020
Long-term complete remission of primary gastric plasmacytoma following endoscopic resection.
    Annals of hematology, 2017, Volume: 96, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Gastric Mucosa; Gastroscopy; H

2017
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.
    Alimentary pharmacology & therapeutics, 2008, Oct-01, Volume: 28, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Esomeprazole; Helicobacter In

2008
[Proton pump inhibitors, a family of drugs in continuous expansion].
    Minerva gastroenterologica e dietologica, 2000, Volume: 46, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E

2000
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Drugs, 2003, Volume: 63, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2003
Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.
    Helicobacter, 2003, Volume: 8, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic

2003
Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis.
    European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Benzimidazoles; Drug Therapy, Combin

2004
Understanding NSAID-PPI-COX-2 interrelationships.
    Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40 Suppl A

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida

2004
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
    Alimentary pharmacology & therapeutics, 2004, Nov-15, Volume: 20, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D

2004
[Eradication of Helicobacter pylori].
    Krankenpflege Journal, 2005, Volume: 43, Issue:4-6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy,

2005
[Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Benzimidazoles; Drug Therapy, Combin

2005
Triple therapy as a cure for Helicobacter pylori infection.
    European journal of gastroenterology & hepatology, 1996, Volume: 8 Suppl 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimi

1996
The impact of Helicobacter pylori eradication on peptic ulcer healing.
    The American journal of gastroenterology, 1998, Volume: 93, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer

1998
[Role of pantoprazole in the eradicating treatment of Helicobacter pylori].
    Revista clinica espanola, 1998, Volume: 198, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy

1998
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
    Journal of clinical gastroenterology, 1998, Volume: 27 Suppl 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C

1998
Pantoprazole: a new proton pump inhibitor.
    Clinical therapeutics, 2000, Volume: 22, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic

2000
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
    La Revue du praticien, 2001, Apr-15, Volume: 51, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child

2001
[Comparative study of proton pump inhibitors].
    Orvosi hetilap, 2001, Sep-09, Volume: 142, Issue:36

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C

2001
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16 Suppl 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic

2002
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

2002

Trials

112 trials available for pantoprazole and Helicobacter Infections

ArticleYear
Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2019, Volume: 38, Issue:4

    Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therap

2019
Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
    Acta medica portuguesa, 2017, Mar-31, Volume: 30, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Disease

2017
A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule;

2017
Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2018, Volume: 29, Issue:5

    Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Sc

2018
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2013, Volume: 32, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agent

2013
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom

2014
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom

2014
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom

2014
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom

2014
Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial.
    Helicobacter, 2015, Volume: 20, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin;

2015
[Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2014, Volume: 67, Issue:2 Pt 2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th

2014
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
    Medicine, 2015, Volume: 94, Issue:17

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents;

2015
Eradication of gastric Helicobacter pylori ameliorates halitosis and tongue coating.
    The journal of contemporary dental practice, 2015, 03-01, Volume: 16, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

2015
Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
    Digestion, 2015, Volume: 92, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Bismuth; Breath Tests; Clinic

2015
Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study.
    Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec

2016
A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection.
    Medicine, 2015, Volume: 94, Issue:48

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom

2015
Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Clarithromycin; Drug Administration Sche

2017
Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2017, Volume: 28, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Amoxicillin; Anorexia; Anti-Bacteria

2017
[Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 51, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents;

2008
Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon

2009
Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
    Alimentary pharmacology & therapeutics, 2009, May-01, Volume: 29, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; An

2009
Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Breath Tests; Capsules; Carbon Radioisotopes; Citric Acid;

2009
Periodontal therapy improves gastric Helicobacter pylori eradication.
    Journal of dental research, 2009, Volume: 88, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec

2009
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
    Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydr

2010
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-

2010
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-

2010
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-

2010
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-

2010
Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients.
    Southern medical journal, 2009, Volume: 102, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diabete

2009
The effect of mastic gum on Helicobacter pylori: a randomized pilot study.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2010, Volume: 17, Issue:3-4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Helicob

2010
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
    The American journal of the medical sciences, 2009, Volume: 338, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2009
Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
    Scandinavian journal of gastroenterology, 2010, Volume: 45, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Biopsy; Clarithro

2010
Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin.
    Helicobacter, 2010, Volume: 15, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Animals; Anti-Bacterial Agents; Female;

2010
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
    Digestion, 2010, Volume: 82, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infectiv

2010
Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus.
    Southern medical journal, 2010, Volume: 103, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diab

2010
Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer

2011
Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bism

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Helicobacter, 2011, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective

2011
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cl

2011
Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitor treatment: are G-protein β3 subunit genotype, Helicobacter pylori status, and environmental factors response modifiers?
    Digestion, 2011, Volume: 84, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Alcohol Drinking; Anti-Inflammato

2011
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
    Helicobacter, 2012, Volume: 17, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarith

2012
Effective administration method of intravenous proton pump inhibitor: a novel testing using a BRAVO catheterless pH monitoring system.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2011, Volume: 22, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Analysis of Variance; Female; Gastric Acidity Determi

2011
[Enterofuril eradication therapy in chronic inflammatory diseases of the upper digestive tract].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2011, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Chronic Disease; Clarithromyc

2011
Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Dose-Response Relationship, Drug;

2012
A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
    Helicobacter, 2012, Volume: 17, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents

2012
The efficacy of PPI after endoscopic hemostasis in patients with bleeding peptic ulcer and role of Helicobacter pylori.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2012, Volume: 66, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacte

2012
Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
    World journal of gastroenterology, 2012, Aug-28, Volume: 18, Issue:32

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compou

2012
Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.
    Helicobacter, 2013, Volume: 18, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2013
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

2002
[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection].
    Zhonghua yi xue za zhi, 2002, Sep-25, Volume: 82, Issue:18

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti

2002
Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Breath Tests; Dose-Response Relations

2003
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies.
    Alimentary pharmacology & therapeutics, 2003, May-01, Volume: 17, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be

2003
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
    The Netherlands journal of medicine, 2003, Volume: 61, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Ag

2003
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
    Alimentary pharmacology & therapeutics, 2003, Oct-15, Volume: 18, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents

2003
Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
    Helicobacter, 2003, Volume: 8, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An

2003
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Alimentary pharmacology & therapeutics, 2004, Jul-01, Volume: 20, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; B

2004
Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection.
    Journal of the Chinese Medical Association : JCMA, 2004, Volume: 67, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

2004
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
    Hepato-gastroenterology, 2003, Volume: 50 Suppl 2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

2003
The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing.
    Current medical research and opinion, 2004, Volume: 20, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2004
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben

2004
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
    World journal of gastroenterology, 2005, Apr-21, Volume: 11, Issue:15

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles;

2005
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2004, Volume: 15, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2004
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-

2005
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-

2005
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-

2005
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-

2005
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study.
    Gerontology, 2006, Volume: 52, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents

2006
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2006, Volume: 17, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infect

2006
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteri

2006
Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2006, Volume: 57 Suppl 3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An

2006
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A

2007
Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Body Constitution; Cross-Over Stu

2007
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Adminis

2007
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure?
    Helicobacter, 2007, Volume: 12, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Adult; Aged; Curcumin; Drug Therapy, Combin

2007
Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.
    Helicobacter, 2007, Volume: 12, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents

2007
A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey.
    Helicobacter, 2007, Volume: 12, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Sch

2007
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
    Helicobacter, 2007, Volume: 12, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug

2007
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
    Journal of gastroenterology, 2008, Volume: 43, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarit

2008
Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Clinical therapeutics, 2008, Volume: 30, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents

2008
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].
    Leber, Magen, Darm, 1995, Volume: 25, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid

1995
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
    Deutsche medizinische Wochenschrift (1946), 1995, Mar-17, Volume: 120, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom

1995
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer.
    Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

1997
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
    The American journal of gastroenterology, 1997, Volume: 92, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C

1997
Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing.
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

1998
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori.
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti

1998
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti

1998
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
    Helicobacter, 1998, Volume: 3, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents

1998
Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group.
    The American journal of gastroenterology, 1998, Volume: 93, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial

1998
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
    European journal of gastroenterology & hepatology, 1999, Volume: 11, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer

1999
Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week.
    Digestion, 1999, Volume: 60, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Cla

1999
One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases.
    Digestion, 1999, Volume: 60, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimid

1999
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
    Gastroenterology, 1999, Volume: 117, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Double-Blind Method; Enzyme In

1999
Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy.
    Helicobacter, 1999, Volume: 4, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents

1999
Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection.
    Revista espanola de enfermedades digestivas, 1999, Volume: 91, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

1999
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
    Scandinavian journal of gastroenterology, 1999, Volume: 34, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial

1999
Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
    Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents

1999
Pantoprazole suppresses Helicobacter pylori without affecting cure.
    Helicobacter, 1999, Volume: 4, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Thera

1999
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz

2000
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

2000
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
    Helicobacter, 2000, Volume: 5, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul

2000
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
    Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bism

2000
One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
    European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

2000
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer].
    Medicinski arhiv, 2000, Volume: 54, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2000
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Aging; Amoxicillin; Anti-Bacterial Agent

2000
Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2000
Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up.
    Journal of clinical gastroenterology, 2000, Volume: 31, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

2000
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles

2000
Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Azithromycin; Benzimidazoles; Drug Therapy, Co

2000
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.
    Digestion, 2001, Volume: 63, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz

2001
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz

2001
cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia.
    Journal of clinical microbiology, 2001, Volume: 39, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

2001
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Benz

2001
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles;

2001
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter

2001
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Aged, 80 and over; Aging; Amoxi

2001
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

2001
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz

2001
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).
    Wiener klinische Wochenschrift, 2001, Dec-17, Volume: 113, Issue:23-24

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D

2001
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Car

2002
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2002, Volume: 55, Issue:1-2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Candida albicans;

2002
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2002, Volume: 15, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzi

2002

Other Studies

66 other studies available for pantoprazole and Helicobacter Infections

ArticleYear
Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
    Helicobacter, 2020, Volume: 25, Issue:2

    Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Female; Helicobac

2020
The Relationship between the Sydney Classification and the First-Line Treatment Efficacy in Helicobacter-Associated Gastritis.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2020, Volume: 29, Issue:6

    Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Clinic

2020
[Trend in the Eradication Rates of
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2017, 11-25, Volume: 70, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati

2017
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
    Helicobacter, 2018, Volume: 23, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Adult; Anti-Bacterial Agents; Bacteroidetes

2018
Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis.
    The Korean journal of internal medicine, 2019, Volume: 34, Issue:5

    Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Cytochrome P-450 CYP2C19;

2019
Case report: Helicobacter suis infection in a pig veterinarian.
    Helicobacter, 2013, Volume: 18, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Animals; Anti-Bacterial Agents; Clarith

2013
Might Helicobacter pylori infection be associated with distortion on taste perception?
    Medical hypotheses, 2013, Volume: 81, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Clarithromycin; Dysgeusia; Female; G

2013
Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication.
    World journal of gastroenterology, 2013, Nov-14, Volume: 19, Issue:42

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; C

2013
Not All Helicobacter Are pylori.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Biopsy; Clarithromycin;

2015
Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?
    BMC gastroenterology, 2015, Feb-15, Volume: 15

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes

2015
In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation.
    Archiv der Pharmazie, 2015, Volume: 348, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Ba

2015
Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus.
    Journal of digestive diseases, 2015, Volume: 16, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Diabetes M

2015
Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study.
    American journal of clinical dermatology, 2015, Volume: 16, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Chi-Square Distribution; Chronic Diseas

2015
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
    BMC gastroenterology, 2015, Dec-03, Volume: 15

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2015
Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.
    Helicobacter, 2016, Volume: 21, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; D

2016
Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Cytoc

2016
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series.
    Medicine, 2016, Volume: 95, Issue:15

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Drug Therapy, Combination; Female; H

2016
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 120, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; ATP Binding Cassette Transport

2017
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
    Minerva gastroenterologica e dietologica, 2017, Volume: 63, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents;

2017
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:8 Pt 1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon

2008
[Eosinophilic gastritis after helicobacter pylori eradication].
    Zeitschrift fur Gastroenterologie, 2008, Volume: 46, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop

2008
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 52, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2008
Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori.
    World journal of gastroenterology, 2009, Dec-07, Volume: 15, Issue:45

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Burkitt Lymphoma; Female; Gastric

2009
Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation.
    Southern medical journal, 2010, Volume: 103, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; C-Reactive Prote

2010
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial

2010
[Acute psychosis induced by a Helicobacter pylori (H. pylori)-eradication treatment with amoxicillin, clarithromycin and pantoprazole].
    Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2010, Volume: 24, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2010
Effect of Helicobacter pylori infection on symptoms of gastroenteritis due to enteropathogenic Escherichia coli in adults.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Diarrhea; Enteropathogenic Escher

2011
Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on?
    Journal of digestive diseases, 2010, Volume: 11, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial

2010
Sequential therapy for Helicobacter pylori eradication.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2010, Volume: 21, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents

2010
[A case of Menetrier's disease showing mucus bridge observed during endoscopy].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, Volume: 57, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th

2011
Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease.
    Scandinavian journal of gastroenterology, 2011, Volume: 46, Issue:7-8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Esophagogastric Junction; Female; G

2011
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent

2012
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent

2012
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent

2012
Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent

2012
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, Volume: 58, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di

2011
Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esophagitis, Peptic; Female; Gastric Mucosa; Helicob

2012
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.
    Journal of clinical gastroenterology, 2002, Volume: 35, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infect

2002
[Patient with increased stomach cancer risk. Helicobacter can cause damage here].
    MMW Fortschritte der Medizin, 2002, Oct-24, Volume: 144, Issue:43

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy,

2002
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
    Revista espanola de enfermedades digestivas, 2003, Volume: 95, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy,

2003
Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers.
    Saudi medical journal, 2004, Volume: 25, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Develop

2004
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
    Journal of gastroenterology, 2004, Volume: 39, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles;

2004
[The effect of Helicobacter pylori eradication on prokinetic treatment on the quality of life in functional dyspepsia].
    Orvosi hetilap, 2004, Oct-17, Volume: 145, Issue:42

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles

2004
Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cell Count;

2005
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa

2005
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    European journal of clinical pharmacology, 2005, Volume: 61, Issue:5-6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl

2005
Helicobacter pylori: factors affecting eradication and recurrence.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

2005
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
    Alimentary pharmacology & therapeutics, 2006, Feb-15, Volume: 23, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial

2006
Comparison of pantoprazole- vs. omeprazole- based triple therapy regimens in the treatment of Helicobacter pylori infection and duodenal ulcer healing in a Turkish population.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2005, Volume: 16, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti

2005
Eradication of Helicobacter pylori and dosages of esomeprazole.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-

2006
Thyroxine in goiter, H. pylori infection, and gastritis.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adsorption; Anti-Ulcer Agents; Benzimidazoles; Biological A

2006
Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial

2007
What is the best first choice treatment option for Helicobacter pylori?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2007, Volume: 18, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Ag

2007
[Reliable Helicobacter eradication. Combination package facilitates therapy].
    MMW Fortschritte der Medizin, 2006, Nov-09, Volume: 148, Issue:45

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Packag

2006
Efficacy of clarithromycin-based triple therapy for treating Helicobacter pylori in Thai non-ulcer dyspeptic patients with clarithromycin-resistant strains.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89 Suppl 3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent

2006
The eradication of Helicobacter pylori is affected by body mass index (BMI).
    Obesity surgery, 2008, Volume: 18, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Body

2008
[Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician].
    Deutsche medizinische Wochenschrift (1946), 1998, Jan-30, Volume: 123, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Female; He

1998
[Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].
    Medizinische Klinik (Munich, Germany : 1983), 1998, Feb-15, Volume: 93, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An

1998
Treatment of antibiotic-resistant Helicobacter pylori.
    The New England journal of medicine, 1998, Jul-02, Volume: 339, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D

1998
Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication.
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti

1998
[Is dental plaque a normal Helicobacter pylori reservoir?].
    Acta gastroenterologica Latinoamericana, 1998, Volume: 28, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Benzimidazoles; Clari

1998
Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male.
    Zeitschrift fur Gastroenterologie, 1998, Volume: 36, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases;

1998
Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers.
    Thrombosis research, 2000, Mar-15, Volume: 97, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute-Phase Reaction; Adult; Aged; Anti-Bacterial Agents; A

2000
Treatment of Helicobacter pylori infection: is less more?
    Journal of clinical gastroenterology, 2000, Volume: 31, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz

2000
Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients.
    Journal of gastroenterology and hepatology, 2000, Volume: 15, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer

2000
Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients.
    The American journal of medicine, 2000, Volume: 108, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Amoxicillin; Anti-Ulcer Agents;

2000
Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study.
    Croatian medical journal, 2001, Volume: 42, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles

2001
Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz

2001
Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
    Scandinavian journal of gastroenterology, 1992, Volume: 27, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Benzimidazoles; Duodenal Ulcer;

1992
chemdatabank.com